Bank of New York Mellon Corp - ALDEYRA THERAPEUTICS INC ownership

ALDEYRA THERAPEUTICS INC's ticker is ALDX and the CUSIP is 01438T106. A total of 97 filers reported holding ALDEYRA THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.35 and the average weighting 0.4%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of ALDEYRA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,184,785
-20.5%
177,363
-0.1%
0.00%
Q2 2023$1,490,039
+126.3%
177,597
+167.9%
0.00%
Q1 2023$658,389
+43.2%
66,303
+0.4%
0.00%
Q4 2022$459,638
+29.8%
66,040
-0.3%
0.00%
Q3 2022$354,000
+12.7%
66,222
-15.6%
0.00%
Q2 2022$314,000
-66.3%
78,475
-62.6%
0.00%
Q1 2022$932,000
+24.4%
209,815
+12.2%
0.00%
Q4 2021$749,000
-53.6%
187,067
+1.8%
0.00%
Q3 2021$1,614,000
-35.9%
183,809
-17.2%
0.00%
Q2 2021$2,516,000
+346.9%
222,001
+368.8%
0.00%
Q1 2021$563,000
+45.1%
47,354
-16.4%
0.00%
Q4 2020$388,000
+237.4%
56,674
+264.5%
0.00%
Q3 2020$115,000
+76.9%
15,5480.0%0.00%
Q2 2020$65,000
-60.6%
15,548
-76.7%
0.00%
Q1 2020$165,000
-61.7%
66,794
-10.1%
0.00%
Q4 2019$431,000
+5.4%
74,257
-4.2%
0.00%
Q3 2019$409,000
-9.5%
77,547
+2.9%
0.00%
Q2 2019$452,000
-28.4%
75,353
+7.7%
0.00%
Q1 2019$631,000
-45.4%
69,947
-49.8%
0.00%
Q4 2018$1,156,000
-35.6%
139,305
+7.1%
0.00%
Q3 2018$1,795,000
+353.3%
130,015
+160.9%
0.00%
Q2 2018$396,000
+153.8%
49,842
+139.7%
0.00%
Q1 2018$156,000
+24.8%
20,791
+13.1%
0.00%
Q4 2017$125,000
-6.7%
18,378
-1.0%
0.00%
Q3 2017$134,00018,5700.00%
Other shareholders
ALDEYRA THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Knoll Capital Management, LLC 3,031,915$20,253,19221.02%
Perceptive Advisors 11,350,085$75,818,5682.53%
JOHNSON & JOHNSON 394,834$2,637,4910.97%
Joseph P. Lucia & Associates, LLC 28,331$189,2510.13%
WOODSTOCK CORP 137,179$916,3560.12%
Palo Alto Investors LP 160,800$1,074,1440.10%
Affinity Asset Advisors, LLC 44,348$296,2450.08%
Verition Fund Management LLC 935,273$6,247,6240.07%
FOX RUN MANAGEMENT, L.L.C. 33,519$223,9070.07%
TOBIAS FINANCIAL ADVISORS, INC. 34,173$228,2760.06%
View complete list of ALDEYRA THERAPEUTICS INC shareholders